化学療法誘発性悪心・嘔吐 (CINV) 治療薬の世界市場 (2015〜2019年)

化学療法誘発性悪心・嘔吐 (CINV) とは、化学療法の副作用の中でも特に重篤なものです。場合によっては、化学療法で治癒可能ながんであっても治療の延期・拒否をせざるを得ないこともあります。また、化学療法に伴う悪心・嘔吐は患者のQoL (生活の質) を著しく低下させます。CINVの神経伝達物質となるのが、ドーパミンや5-HT3、物質P、内在性カンナビノイドなどです。CINVは、腹部の求心性迷走神経による嘔吐中枢の刺激や、最後野のCTZ (化学受容器引金帯) の直接的刺激により発症します。CINVの種類により、様々な治療法が処方されます。CINVの治療に用いられている薬剤クラスには、5-HT3受容体拮抗薬やNK15-HT3受容体拮抗薬、コルチコステロイド、ドーパミン拮抗薬、ベンゾジアペピン、カンナビノイドなどがあります。現在使われている治療薬の大半が嘔吐防止に役立ちますが、悪心の治療効果は限られています。世界の化学療法誘発性悪心・嘔吐 (CINV) 治療薬市場は2014〜2019年にかけて、4.9%の年平均成長率 (CAGR) で成長する見通しです。

当レポートでは、世界の化学療法誘発性悪心・嘔吐 (CINV) 治療薬の市場について分析し、疾患の概要や市場の基本構造、市場規模の動向 (今後5年間の予測値)、薬剤の投与経路別・薬剤クラス別・治療法別および疾患の発現時期別の詳細動向、地域市場の構造・動向と規制体制、市場の促進・抑制要因とその影響力、主要企業・製品のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブサマリー

• 分析結果の概略

第2章 分析範囲

• 分析概要
• 大手ベンダーの主要製品

第3章 市場分析の手法

• 分析手法
• 経済指標

第4章 イントロダクション

• 市場動向の概略

第5章 製品プロファイル

• Zofran
• Aloxi/Onicit/Paloxi
• Akynzeo
• Emend

第6章 疾患概要

• 疾患に対する理解
• 病態整理
• CINVの種類
• 原因
• リスク要因
• 管理
• 経済的負担

第7章 CINV関連の規制ガイドライン

第8章 パイプライン分析

第9章 市場環境

• 市場概要
• 市場規模とその予測
• 米国のCINV治療薬市場
• ファイブフォース分析

第10章 投与経路 (ROA) 別の市場区分

• 経口薬
• 非経口薬
• 経皮パッチ

第11章 CINVの発現時期別の市場区分

• 急性CINV
• 遅延性CINV
• 予測性CINV
• 突出性CINV

第12章 治療薬の薬理学的クラス別の市場区分

• 5-HT3受容体拮抗薬
• NK-1受容体拮抗薬
• コルチコステロイド
• ドーパミン受容体拮抗薬
• ベンゾジアペピン
• カンナビノイド

第13章 治療法の種類別の市場区分

• 単剤療法
• 併用療法

第14章 地域区分

第15章 市場成長の促進要因

第16章 促進要因とその影響力

第17章 市場の課題

第18章 促進要因・課題の影響力

第19章 市場の動向

第20章 ベンダー環境

• 競争シナリオ
• 市場シェア分析
• その他の有力ベンダー

第21章 主要ベンダーの分析

• GlaxoSmithKline
• Helsinn
• Heron
• Merck & Co. Inc.
• Tesaro

第22章 付録

• 略語集

図表一覧

About CINV

CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

Technavio's analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.

Technavio's report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

• Americas
• APAC
• EMEA

Key vendors

• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck & Co
• Tesaro

Other Prominent Vendors

• Acacia Pharma
• Aphios
• Barr Laboratories
• Baxter Healthcare
• Eisai
• Especificos Stendhal
• F.Hoffmann La Roche
• Mundipharma
• Mylan Pharmaceuticals
• OPKO Health
• Orchid Healthcare
• Otsuka Pharmaceutical
• ProStrakan
• Sandoz (Novartis)
• Solvay Pharmaceuticals
• Specialised Therapeutics Australia
• Sun Pharma
• Taiho Pharmaceutical
• Teva Pharmaceuticals

Market driver

• Increase in incidence and prevalence of cancer
• For a full, detailed list, view our report

Market challenge

• Complex physiology of CINV
• For a full, detailed list, view our report

Market trend

• Increased use of combination therapies
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: Product profiles

• Zofran
• Aloxi/Onicit/Paloxi
• Akynzeo
• Emend

PART 06: Disease Overview

• Understanding the disease
• Pathophysiology
• Types of CINV
• Causes
• Risk factors
• Management
• Economic burden

PART 07: Regulatory guidelines on CINV

PART 08: Pipeline analysis

PART 09: Market landscape

• Market overview
• Market size and forecast
• CINV Drugs Market in US
• Five forces analysis

PART 10: Market segmentation by ROA

• Oral
• Parenteral
• Transdermal patch

PART 11: Market segmentation by onset of disease in CINV

• Acute CINV
• Delayed CINV
• Anticipatory CINV
• Breakthrough CINV

PART 12: Market segmentation by pharmacological class of drugs

• 5-HT3 Receptor Antagonists
• NK-1 Receptor Antagonists
• Corticosteroids
• Dopamine Receptor Antagonists
• Benzodiazepines
• Cannabinoids

PART 13: Market segmentation by type of therapy

• Monotherapy
• Combination therapy

PART 14: Geographical segmentation

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape

• Competitive Scenario
• Market Share Analysis 2014
• Other prominent vendors

PART 21: Key vendor analysis

• GlaxoSmithKline
• Helsinn
• Heron
• Merck & Co. Inc.
• Tesaro

PART 22: Appendix

• List of abbreviation

List of Exhibits:

• Exhibit 01: Product offerings
• Exhibit 02: Types of CINV
• Exhibit 03: Causes of emesis
• Exhibit 04: Chemotherapeutic agents related emetic risk
• Exhibit 05: Management of CINV
• Exhibit 06: Summary of regulatory guidelines by ASCO, ESMO, MASCC, and NCCN for CINV treatment
• Exhibit 07: Global CINV drugs market: Pipeline portfolio
• Exhibit 08: Global CINV drugs market 2014-2019 ($ millions)
• Exhibit 09: CINV drugs market in US 2014-2019 ($ millions)
• Exhibit 10: Five forces analysis
• Exhibit 11: Segmentation of global CINV drugs market by ROA
• Exhibit 12: Global CINV drugs market segment by onset of disease
• Exhibit 13: Global CINV drugs market segment by pharmacological class of drugs
• Exhibit 14: Global CINV drugs market segment by type of therapy
• Exhibit 15: Segmentation of Global CINV Drugs Market by Geography 2014
• Exhibit 16: Drivers of global CINV drugs market
• Exhibit 17: Impact of drivers
• Exhibit 18: Challenges of global CINV drugs market
• Exhibit 19: Impact of drivers and challenges
• Exhibit 20: YoY growth and revenue of Emend 2011-2014 ($ millions)
• Exhibit 21: GlaxoSmithKline: Business segmentation by revenue 2014
• Exhibit 22: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
• Exhibit 23: GlaxoSmithKline: Geographical segmentation by revenue 2014
• Exhibit 24: Helsinn: products
• Exhibit 25: Helsinn: Key pipeline products
• Exhibit 26: Helsinn: Geographical presence
• Exhibit 27: Heron: Product Pipeline
• Exhibit 28: Merck & Co. Inc.: Business segmentation by revenue 2013
• Exhibit 29: Merck & Co. Inc.: Business segmentation by revenue 2012 and 2013 (US$ billions)
• Exhibit 30: Merck & Co. Inc.: Sales by geography 2013
• Exhibit 31: Tesaro : Product segmentation
• Exhibit 32: Tesaro : Geographical presence